fda regulatory & compliance symposium cambridge, august 26, 2005
DESCRIPTION
Drug Safety Strengthened by Technology and Data Integrity Lisa Olson, SEC Associates, Inc. FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005. Agenda?. What's Going on Now? Some Problem Areas What's Changing? How is Risk Manifested? Important Focus - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/1.jpg)
FDA Regulatory & Compliance SymposiumCambridge, August 26, 2005
Drug Safety Strengthened by Technology and Data Integrity
Lisa Olson, SEC Associates, Inc.
![Page 2: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/2.jpg)
© 2005 SEC Associates, Inc. 2
Agenda?
• What's Going on Now?• Some Problem Areas• What's Changing?• How is Risk Manifested?• Important Focus• Business Value of Accurate Systems
![Page 3: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/3.jpg)
© 2005 SEC Associates, Inc. 3
What's Going On Now?
![Page 4: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/4.jpg)
© 2005 SEC Associates, Inc. 4
Current Environment
• Product problems• Need to see early signals• Increasing interactions
– Multiple chronic conditions– Insurance promoting the "quick fix"
(drug)
• Physicians are rushed
![Page 5: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/5.jpg)
© 2005 SEC Associates, Inc. 5
Current Environment
• Pressures– Congress– Patient– Industry– Various organizations (trade, patient
advocacy, disease research)
• Need/want to look at safety from research through to manufacturing and use
![Page 6: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/6.jpg)
© 2005 SEC Associates, Inc. 6
Current Environment
• FDA– Wants to partner with industry– Pressure to get drugs to market quickly– Yet, under scrutiny for not protecting the
public
• Industry– Economic and competitive pressures– Bad press– Changing the way we approach therapies
(more individualized)
![Page 7: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/7.jpg)
© 2005 SEC Associates, Inc. 7
Current Environment
• Move towards electronic health records
• Almost too much information to analyze – large amount of data
• Computer usage increasing – storage, capture, analysis
• Reliance on automation is increasing• Safety measures change and may be
electronic (ECGs, specialty labs)
![Page 8: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/8.jpg)
© 2005 SEC Associates, Inc. 8
Current Environment
• Reduce risks or deal with appropriately throughout life cycle of the product
• Want to be able to look at data cross-program
• Increased interest in quick solutions
AGHGHG!!
![Page 9: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/9.jpg)
© 2005 SEC Associates, Inc. 9
Some Problem Areas
![Page 10: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/10.jpg)
© 2005 SEC Associates, Inc. 10
Problem Areas
• Wide variety of "solutions"• Systems don't talk to each other• Increased outsourcing• More information coming from multiple
parties
![Page 11: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/11.jpg)
© 2005 SEC Associates, Inc. 11
Problem Areas in Research
• Separation of drug safety data from clinical data management (reconciliation task)
• We do QA of CDM – what about SAEs, PVG?– What checks are done on the data?– What about coding – is it accurate?– Versions of dictionaries?
• Any check that periodic safety reports are correct?
![Page 12: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/12.jpg)
© 2005 SEC Associates, Inc. 12
Problem Areas
• We focus on accuracy of collection – what about the analysis?
• Need to ensure availability of data
These problems are solvable, but you do need to address them
![Page 13: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/13.jpg)
© 2005 SEC Associates, Inc. 13
What's Changing?
![Page 14: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/14.jpg)
© 2005 SEC Associates, Inc. 14
Critical Path
• FDA's Critical Path Initiative• Make right decisions based on reliable data• Need better assessment of safety early on• Use new technology, but take care with it• Look at data cross-company (need for
standards)• Want to be able to analyze data quickly,
but watch out for bias which could invalidate study
![Page 15: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/15.jpg)
© 2005 SEC Associates, Inc. 15
What's Different
• Data mining will be critical– Ability to slice and dice – Ability to quickly aggregate– But must be accurate– Hard to mine, if in multiple places
• Health (medical) records vs. clinical trial records – can they be the same?
![Page 16: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/16.jpg)
© 2005 SEC Associates, Inc. 16
What's Different
• Importance of PAT – finding a process or measurement problem that might cross products
• Consider infrastructure that is needed– Staff roles changing– QA staff vs. scientists– Computer security– Analysis tools – training!
![Page 17: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/17.jpg)
© 2005 SEC Associates, Inc. 17
How is Risk Manifested?
![Page 18: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/18.jpg)
© 2005 SEC Associates, Inc. 18
Risk
• Wrong decisions based on bad data• Data being changed inappropriately• Misrepresented results (not
necessarily an error message!)• Unavailability of data/records
– Technology issues– Training
![Page 19: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/19.jpg)
© 2005 SEC Associates, Inc. 19
Risk
To Patient?
Or risk of getting caught?
![Page 20: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/20.jpg)
© 2005 SEC Associates, Inc. 20
Important Focus
![Page 21: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/21.jpg)
© 2005 SEC Associates, Inc. 21
Realize Impact of:
• Inaccurate software• Incorrect use• Control over changes• Integrity controls• Security
![Page 22: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/22.jpg)
© 2005 SEC Associates, Inc. 22
What Else Is Important
• Employing the right skills• Auditing/verifying suppliers – know
what you're buying!• Compliance (this is implied, but maybe
shouldn't be)– Clinical investigators
• Compliance is everyone's responsibility– All uses– All analyses
![Page 23: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/23.jpg)
© 2005 SEC Associates, Inc. 23
Business Value of Accurate Systems
![Page 24: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/24.jpg)
© 2005 SEC Associates, Inc. 24
The "V" Word
What does "validation" mean?
Simply, is it working correctly? (And can you prove it?)
Why is this a bad thing?
![Page 25: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/25.jpg)
© 2005 SEC Associates, Inc. 25
Validation
• Arguments:– "It takes too long – let's just put it in and
fix it later"– "I'm buying it – the vendor should
ensure it's correct"– "Nobody else is doing this"– "We won't get inspected"– "We'll know if it's not working"
![Page 26: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/26.jpg)
© 2005 SEC Associates, Inc. 26
A Contradiction
• We are tending to trust computers more at a time when:– Impact of software bugs is greater– Timelines are too short to build in
quality– We are trying to link incompatible things
together– Security exposures are increasing– We are using other companies (and their
systems) to do our processes, without adequate investigation
![Page 27: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/27.jpg)
© 2005 SEC Associates, Inc. 27
Value
• Get things right the first time (more expensive to fix and patch)
• Decrease overall costs of system deployments
• Avoid making wrong decisions based on incorrect data
![Page 28: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/28.jpg)
© 2005 SEC Associates, Inc. 28
Value
• "Hidden" costs– Company reputation– Staff confidence
• Partner with suppliers – get better products
• Minimize risks – appropriate mitigation• React vs. prevent• Not an add-on; just part of your
business
![Page 29: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/29.jpg)
© 2005 SEC Associates, Inc. 29
In Summary
![Page 30: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/30.jpg)
© 2005 SEC Associates, Inc. 30
In Summary
• For safety, remember the importance of:– Accurate data– The right data– Availability / timeliness
• Use technology, but make sure it's right!
![Page 31: FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005](https://reader035.vdocuments.net/reader035/viewer/2022070405/56813f63550346895daa3685/html5/thumbnails/31.jpg)
© 2005 SEC Associates, Inc. 31
Thank You! Thank You!
Lisa OlsonPrincipal ConsultantSEC Associates, Inc.
2100 Gateway Centre Blvd., Suite 150Morrisville, NC 27560
Phone: (919) 532-1241 Fax: (919) 467-1109